Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 5,887 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 5,887 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $22.74, for a total value of $133,870.38. Following the completion of the transaction, the insider owned 215,747 shares in the company, valued at $4,906,086.78. The trade was a 2.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS traded up $1.16 during midday trading on Monday, hitting $23.99. The company had a trading volume of 373,728 shares, compared to its average volume of 404,856. The business’s 50-day simple moving average is $22.62 and its 200-day simple moving average is $22.48. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The company had revenue of $28.64 million during the quarter. On average, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KMTS. Price T Rowe Associates Inc. MD increased its stake in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares during the period. Franklin Resources Inc. increased its position in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the period. Millennium Management LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $11,036,000. Brown Advisory Inc. increased its holdings in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares during the period. Finally, Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies during the fourth quarter worth $9,282,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KMTS. Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.